Distinctive BsAb Platform The problem of chain mismatches will reduce the yield of the bsAb, increase the difficulty of purification, and increase the production cost. Therefore, obtaining a correctly assembled bsAb hasRead More…
Overview of Bispecific Antibody Drug Technology (Part I)
Bispecific antibody (bsAb) refers to a molecule that can bind to two different antigens or to two different epitopes of the same antigen. The concept of bsAbs was first proposed by NisonoffRead More…
Bispecific Antibodies Targeting Dual Tumor-associated Antigens
In the past two decades, advances in biotechnology have brought improvements in protein engineering and manufacturing technology, and promoted the development of increasingly complex bispecific antibodies (BsAbs). At present, more than 100Read More…
Difficulties and Prospects in the Research and Development of Bispecific Antibodies
Nowadays, in the tide of research and development of biological agents, antibody drugs are in an explosive period. The major monoclonal antibody (McAb) drugs have accounted for more than half of theRead More…
Current Status of Research and Development of Multispecific Antibodies
Antibody drug research and development has shown explosive growth in the past decade. A total of 31 antibody drugs and 10 antibody biosimilar drugs were approved on the global market from 2013Read More…
How to Develop A Qualified Bispecific Antibody
In 1960, Nisonoff and his collaborators at the Roswell Park Memorial Institute in New York first proposed the original concept of bispecific antibodies (BsAbs). Since then, with the great progress in theRead More…
Amgen Bispecific Antibody BLINCYTO® (blinatumomab) Significantly Prolongs the Overall Survival Time of Patients with Leukemia
Recently, Amgen announced the long-term efficacy of the company’s bispecific antibody Blincyto (blinatumomab) in the treatment of patients with acute lymphoblastic leukemia (ALL) at the European Hematology Association (EHA) conference. The medianRead More…
Recent Advances in Hot Areas of Bispecific Antibodies Such as PARP Inhibitors
In 2018, Loxo Oncology’s “unlimited cancer” targeted therapy Vitrakvi was approved by the U.S. Food and Drug Administration (FDA), becoming the first targeted therapy for patients with neurotrophic receptor tyrosine kinase (NTRK)Read More…
TG Therapeutics’s new anti-CD47 and CD19 therapy TG-1801 enters Phase I clinical practice
TG Therapeutics is a biopharmaceutical company dedicated to developing innovative treatments for patients with B-cell-mediated diseases. Recently, the company announced the launch of TG-1801 ‘s first human Phase I study, a new,Read More…
The World’s First Single-domain Antibody Drug Cablivi is Approved by FDA in the United States
French pharmaceutical giant Sanofi recently announced that the US Food and Drug Administration (FDA) has approved the single-domain antibody (sdAb) drug Cablivi (caplacizumab) combined with plasma exchange and immunosuppressive therapy, for theRead More…